[The Svedberg seminar] – Peptide nucleic acid (PNA)-mediated pretargeting for radionuclide therapy
October 23, 2023 @ 15:15 – 16:15 CEST
Professor of Molecular Biotechnology
Department of Protein Science, KTH
Amelie Eriksson Karlström is Professor of Molecular Biotechnology at the Department of Protein Science, KTH, where her research group is focused on protein engineering, affinity technologies and bioconjugation chemistry for diagnostic and therapeutic applications. Amelie Eriksson Karlström has a background in solid phase peptide synthesis methodology from PhD studies at the Department of Neurochemistry and Neurotoxicology at Stockholm University. She did postdoctoral studies at the Scripps Research Institute, La Jolla, CA, working on catalytic antibodies and display technologies with Profs. Richard A. Lerner and Carlos Barbas, III, before starting her independent research at KTH
Peptide nucleic acid (PNA)-mediated pretargeting for radionuclide therapy
Targeted radionuclide therapy utilizes tumor-specific radiolabeled molecules to deliver cytotoxic radiation to tumor cells. To avoid unwanted exposure of non-tumor organs, a pretargeting strategy can be used, where the tumor-targeting step is uncoupled from the delivery of the toxic radionuclide. The primary agent is administered first and the secondary, radiolabeled agent is administered after the primary agent has accumulated in the tumor and cleared from non-tumor tissue. We have developed and evaluated a system for pretargeting based on the high selectivity and high affinity of peptide nucleic acid (PNA) hybridization. We have demonstrated that the PNA-based pretargeting system gives high tumor-to-normal tissue contrast in vivo both using affibody molecules and monoclonal antibodies as the tumor-targeting agents.
In this seminar, the molecular design and technological aspects of the PNA-based pretargeting system will be discussed. Results from preclinical evaluation of the PNA-based pretargeting strategy will be presented.
Host: Abhimanyu Thakur,UU